{
  "schemaVersion": "2.0.0",
  "identity": {
    "slug": "motif-dot",
    "manufacturerSlug": "motif-neurotech",
    "name": {
      "value": "DOT",
      "status": "verified",
      "sources": [
        {
          "url": "https://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression",
          "label": "Motif Neurotech — FDA IDE for first clinical trial",
          "date": "2026-04-27"
        }
      ],
      "updatedAt": "2026-05-04"
    },
    "modelNumber": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    },
    "codename": {
      "value": "XCS",
      "status": "verified",
      "sources": [
        {
          "url": "https://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression",
          "label": "Motif Neurotech — FDA IDE for first clinical trial",
          "date": "2026-04-27"
        }
      ],
      "updatedAt": "2026-05-04"
    },
    "aliases": {
      "value": [
        "Motif XCS System",
        "Motif Neurotech DOT"
      ],
      "status": "verified",
      "sources": [
        {
          "url": "https://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression",
          "label": "Motif Neurotech — FDA IDE for first clinical trial",
          "date": "2026-04-27"
        }
      ],
      "updatedAt": "2026-05-04"
    },
    "generation": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    },
    "predecessorSlug": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    },
    "successorSlug": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    },
    "tagline": {
      "status": "unknown",
      "sources": [
        {
          "label": "editorial copy — not a sourced fact"
        }
      ],
      "updatedAt": "2026-05-04"
    },
    "shortDescription": {
      "status": "unknown",
      "sources": [
        {
          "label": "editorial prose — not a sourced fact"
        }
      ],
      "updatedAt": "2026-05-04"
    },
    "longDescription": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    },
    "countryOfOrigin": {
      "value": "US",
      "status": "verified",
      "sources": [
        {
          "url": "https://www.motifneuro.tech",
          "label": "Motif Neurotech — official site"
        }
      ],
      "updatedAt": "2026-05-04"
    },
    "releaseDate": {
      "status": "unknown",
      "sources": [
        {
          "label": "Investigational; not yet commercial"
        }
      ],
      "updatedAt": "2026-05-04"
    },
    "announcedDate": {
      "value": "2026-04",
      "status": "verified",
      "sources": [
        {
          "url": "https://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression",
          "label": "Motif Neurotech — FDA IDE for first clinical trial",
          "date": "2026-04-27"
        }
      ],
      "updatedAt": "2026-05-04"
    },
    "discontinuedDate": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    },
    "status": {
      "value": "clinical-trial",
      "status": "verified",
      "sources": [
        {
          "url": "https://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression",
          "label": "Motif Neurotech — FDA IDE for first clinical trial",
          "date": "2026-04-27"
        }
      ],
      "updatedAt": "2026-05-04"
    }
  },
  "classification": {
    "invasiveness": {
      "value": "invasive",
      "status": "verified",
      "sources": [
        {
          "url": "https://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression",
          "label": "Motif Neurotech — FDA IDE for first clinical trial",
          "date": "2026-04-27"
        }
      ],
      "updatedAt": "2026-05-04"
    },
    "modalities": {
      "value": [
        "DBS"
      ],
      "status": "verified",
      "sources": [
        {
          "url": "https://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression",
          "label": "Motif Neurotech — FDA IDE for first clinical trial",
          "date": "2026-04-27"
        }
      ],
      "updatedAt": "2026-05-04"
    },
    "primaryModality": {
      "value": "DBS",
      "status": "verified",
      "sources": [
        {
          "url": "https://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression",
          "label": "Motif Neurotech — FDA IDE for first clinical trial",
          "date": "2026-04-27"
        }
      ],
      "updatedAt": "2026-05-04"
    },
    "direction": {
      "value": "write",
      "status": "verified",
      "sources": [
        {
          "url": "https://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression",
          "label": "Motif Neurotech — FDA IDE for first clinical trial",
          "date": "2026-04-27"
        }
      ],
      "updatedAt": "2026-05-04"
    },
    "category": {
      "value": [
        "medical-implant",
        "stimulation",
        "therapeutic"
      ],
      "status": "verified",
      "sources": [
        {
          "url": "https://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression",
          "label": "Motif Neurotech — FDA IDE for first clinical trial",
          "date": "2026-04-27"
        }
      ],
      "updatedAt": "2026-05-04"
    },
    "formFactor": {
      "value": [
        "cranial-implant"
      ],
      "status": "verified",
      "sources": [
        {
          "url": "https://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression",
          "label": "Motif Neurotech — FDA IDE for first clinical trial",
          "date": "2026-04-27"
        }
      ],
      "updatedAt": "2026-05-04"
    },
    "intendedUseCases": {
      "value": [
        "treatment-resistant depression"
      ],
      "status": "verified",
      "sources": [
        {
          "url": "https://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression",
          "label": "Motif Neurotech — FDA IDE for first clinical trial",
          "date": "2026-04-27"
        },
        {
          "url": "https://www.statnews.com/2026/04/27/motif-neurotech-gets-fda-nod-brain-implant-depression/",
          "label": "STAT News — Motif Neurotech FDA nod",
          "date": "2026-04-27"
        }
      ],
      "updatedAt": "2026-05-04"
    },
    "targetUsers": {
      "value": [
        "psychiatrist",
        "patient-depression"
      ],
      "status": "verified",
      "sources": [
        {
          "url": "https://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression",
          "label": "Motif Neurotech — FDA IDE for first clinical trial",
          "date": "2026-04-27"
        }
      ],
      "updatedAt": "2026-05-04"
    }
  },
  "stimulation": {
    "capable": {
      "value": true,
      "status": "verified",
      "sources": [
        {
          "url": "https://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression",
          "label": "Motif Neurotech — FDA IDE for first clinical trial",
          "date": "2026-04-27"
        }
      ],
      "updatedAt": "2026-05-04"
    }
  },
  "connectivity": {
    "protocols": {
      "value": [
        "proprietary-rf"
      ],
      "status": "verified",
      "sources": [
        {
          "url": "https://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression",
          "label": "Motif Neurotech — FDA IDE for first clinical trial",
          "date": "2026-04-27"
        }
      ],
      "updatedAt": "2026-05-04"
    },
    "bluetoothVersion": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    },
    "bluetoothProfiles": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    },
    "concurrentMode": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    },
    "encryptionInTransit": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    },
    "pairingMethods": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    },
    "cloudSync": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    },
    "offlineRecording": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    }
  },
  "power": {
    "sources": {
      "value": [
        "other"
      ],
      "status": "verified",
      "sources": [
        {
          "url": "https://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression",
          "label": "Motif Neurotech — FDA IDE for first clinical trial",
          "date": "2026-04-27"
        }
      ],
      "updatedAt": "2026-05-04"
    },
    "batteryLifeActiveHours": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    },
    "chargingPort": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    },
    "chargingTimeMinutes": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    },
    "batteryReplaceable": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    },
    "notes": {
      "value": "Battery-less; powered by external transcutaneous wireless link during a daily session.",
      "status": "verified",
      "sources": [
        {
          "url": "https://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression",
          "label": "Motif Neurotech — FDA IDE for first clinical trial",
          "date": "2026-04-27"
        }
      ],
      "updatedAt": "2026-05-04"
    }
  },
  "physical": {
    "weightGrams": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    },
    "dimensions": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    },
    "materials": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    },
    "sizes": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    },
    "headCircumferenceCm": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    },
    "operatingTempC": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    }
  },
  "software": {
    "apps": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    },
    "mobileApp": {
      "value": false,
      "status": "verified",
      "sources": [
        {
          "url": "https://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression",
          "label": "Motif Neurotech — FDA IDE for first clinical trial",
          "date": "2026-04-27"
        }
      ],
      "updatedAt": "2026-05-04"
    },
    "cloudPlatform": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    },
    "offlineMode": {
      "value": true,
      "status": "verified",
      "sources": [
        {
          "url": "https://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression",
          "label": "Motif Neurotech — FDA IDE for first clinical trial",
          "date": "2026-04-27"
        }
      ],
      "updatedAt": "2026-05-04"
    },
    "subscriptionRequired": {
      "value": false,
      "status": "verified",
      "sources": [
        {
          "url": "https://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression",
          "label": "Motif Neurotech — FDA IDE for first clinical trial",
          "date": "2026-04-27"
        }
      ],
      "updatedAt": "2026-05-04"
    },
    "rawDataAccess": {
      "value": false,
      "status": "verified",
      "sources": [
        {
          "url": "https://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression",
          "label": "Motif Neurotech — FDA IDE for first clinical trial",
          "date": "2026-04-27"
        }
      ],
      "updatedAt": "2026-05-04"
    },
    "exportFormats": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    },
    "lslSupport": {
      "value": false,
      "status": "verified",
      "sources": [
        {
          "url": "https://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression",
          "label": "Motif Neurotech — FDA IDE for first clinical trial",
          "date": "2026-04-27"
        }
      ],
      "updatedAt": "2026-05-04"
    },
    "dataOwnership": {
      "value": "manufacturer",
      "status": "verified",
      "sources": [
        {
          "url": "https://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression",
          "label": "Motif Neurotech — FDA IDE for first clinical trial",
          "date": "2026-04-27"
        }
      ],
      "updatedAt": "2026-05-04"
    },
    "privacyPolicyUrl": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    }
  },
  "sdk": {
    "hasSdk": {
      "value": false,
      "status": "verified",
      "sources": [
        {
          "url": "https://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression",
          "label": "Motif Neurotech — FDA IDE for first clinical trial",
          "date": "2026-04-27"
        }
      ],
      "updatedAt": "2026-05-04"
    },
    "docsUrl": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    },
    "openSource": {
      "value": false,
      "status": "verified",
      "sources": [
        {
          "url": "https://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression",
          "label": "Motif Neurotech — FDA IDE for first clinical trial",
          "date": "2026-04-27"
        }
      ],
      "updatedAt": "2026-05-04"
    },
    "languages": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    },
    "webBluetooth": {
      "value": false,
      "status": "verified",
      "sources": [
        {
          "url": "https://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression",
          "label": "Motif Neurotech — FDA IDE for first clinical trial",
          "date": "2026-04-27"
        }
      ],
      "updatedAt": "2026-05-04"
    },
    "rawSampleAccess": {
      "value": false,
      "status": "verified",
      "sources": [
        {
          "url": "https://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression",
          "label": "Motif Neurotech — FDA IDE for first clinical trial",
          "date": "2026-04-27"
        }
      ],
      "updatedAt": "2026-05-04"
    },
    "bciParadigms": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    },
    "thirdPartyIntegrations": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    }
  },
  "regulatory": {
    "fdaStatus": {
      "value": "breakthrough-device",
      "status": "verified",
      "sources": [
        {
          "url": "https://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression",
          "label": "Motif Neurotech — FDA IDE for first clinical trial",
          "date": "2026-04-27"
        }
      ],
      "updatedAt": "2026-05-04"
    },
    "ceMark": {
      "value": false,
      "status": "verified",
      "sources": [
        {
          "url": "https://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression",
          "label": "Motif Neurotech — FDA IDE for first clinical trial",
          "date": "2026-04-27"
        }
      ],
      "updatedAt": "2026-05-04"
    },
    "certifications": {
      "value": [
        "FDA Breakthrough Device",
        "FDA IDE — RESONATE Early Feasibility Study"
      ],
      "status": "verified",
      "sources": [
        {
          "url": "https://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression",
          "label": "Motif Neurotech — FDA IDE for first clinical trial",
          "date": "2026-04-27"
        }
      ],
      "updatedAt": "2026-05-04"
    },
    "prescriptionRequired": {
      "value": true,
      "status": "verified",
      "sources": [
        {
          "url": "https://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression",
          "label": "Motif Neurotech — FDA IDE for first clinical trial",
          "date": "2026-04-27"
        }
      ],
      "updatedAt": "2026-05-04"
    },
    "pediatricApproved": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    }
  },
  "pricing": {
    "msrp": {
      "status": "unknown",
      "sources": [
        {
          "label": "Investigational — not commercially available"
        }
      ],
      "updatedAt": "2026-05-04"
    },
    "currentPrice": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    },
    "subscription": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    },
    "buyUrls": {
      "status": "unknown",
      "sources": [
        {
          "label": "Investigational — no buy URL"
        }
      ],
      "updatedAt": "2026-05-04"
    },
    "warranty": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    },
    "returnPolicyDays": {
      "status": "unknown",
      "updatedAt": "2026-05-04"
    }
  },
  "editorial": {
    "pros": [
      "Far less invasive than DBS — outpatient ~20-min procedure",
      "Battery-less wireless implant"
    ],
    "cons": [
      "Pre-commercial / Early Feasibility",
      "Requires daily external power session"
    ],
    "bestFor": [],
    "notFor": [],
    "comparableDevices": [
      "medtronic-percept-pc",
      "neuropace-rns"
    ]
  },
  "provenance": {
    "sources": [
      {
        "label": "Motif Neurotech — official site",
        "url": "https://www.motifneuro.tech"
      },
      {
        "label": "BusinessWire — Motif FDA IDE for first trial (2026)",
        "url": "https://www.businesswire.com/news/home/20260427361988/en/Motif-Neurotech-Receives-FDA-Approval-to-Begin-First-Clinical-Trial-of-its-Therapeutic-BCI-for-Treatment-Resistant-Depression"
      },
      {
        "label": "STAT News — Motif Neurotech FDA nod",
        "url": "https://www.statnews.com/2026/04/27/motif-neurotech-gets-fda-nod-brain-implant-depression/"
      }
    ],
    "lastReviewedAt": "2026-05-07"
  }
}